Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial
Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers. The findings are published in Blood Cancer Discovery.
A Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) has shown promising results for enhanced CAR T-cell therapy in B-cell blood cancers. The study, published in Blood Cancer Discovery, targeted three proteins—CD19, CD20, and CD22—along with a fourth protein called OX40 to boost the immune response in patients.
This approach resulted in remission in mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. CAR T-cell therapy has been effective in treating B-cell blood cancers, but many patients experience relapse within a year, leaving limited treatment options. The trial, involving 18 patients with a median age of 64, demonstrated the feasibility of rapid manufacturing and infusion of fresh cells, resulting in positive outcomes with minimal side effects.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
